


Lipid-Derived autacoids


1. Platelet activating factor (PAF).

2. Eicosanoids

□ Leukotrienes

□ Prostanoids





Platelet aggregating factor (PAF)

- **Produced by platelets, macrophages and eosinophils**
- **Platelet aggregation**
- **mediator of inflammation**
- **Vasodilatation**
- **Increased capillary permeability (Oedema)**
- **Chemotactic for leucocytes**
- **smooth muscles contraction (bronchoconstriction).**

Leukotrienes

- Mediators of inflammation and allergy in asthma.
- Vasodilatation.
- Increase capillary permeability.
- Bronchoconstriction.
- Chemotactic action.
- Intestinal contraction

Types

LTA₄

LTB₄ (Chemotaxis)

LTC₄, LTD₄, LTE₄ (Bronchoconstriction)

Leukotriene Blockers

Treatment of asthma

Zileuton (5-Lipo-oxygenase inhibitor).

Zafilurkast (Leukotriene D4 antagonist).

Prostaglandins

Chemistry

Synthesis

the action of Phospholipase A2 on arachidonic acid and then by cyclooxygenase to PGs.

Metabolism

PG dehydrogenase

Types

Prostacyclin (PGI₂) - PGE₂ - PGF₂ α - PGD₂

TABLE 13-1 Physiologic and pharmacologic effects of prostaglandins and related eicosanoids

Biologic process	Eicosanoid	Effect
Reproduction	PGE ₂ PGF _{2α}	Contract pregnant uterus Destruct corpus luteum Contract pregnant uterus
Blood pressure regulation	PGE ₁ , PGE ₂ , PGI ₂ PGF _{2α} TXA ₂	Dilate blood vessels Constrict veins Constrict arteries
Gastric secretion	PGE ₁ , PGE ₂ PGF _{2α} , LTC ₄ , LTD ₄	Contract longitudinal smooth muscle, stimulate bicarbonate secretion Contract smooth muscle
Inflammation	PGE ₁ , PGE ₂ , PGI ₂ LTB ₄ LTC ₄ , LTD ₄	Increase local blood flow, increase vascular permeability Chemotactic for leukocytes Increase vascular permeability
Bronchoconstriction	PGD ₂ , PGF _{2α} , TXA ₂ , LTC ₄ , LTD ₄ PGE ₁ , PGE ₂ , PGI ₂	Cause bronchoconstriction Cause bronchodilation
Platelet aggregation	PGE ₁ , PGD ₂ , PGI ₂ PGG ₂ , PGH ₂ , TXA ₂	Inhibit platelet aggregation Induce platelet aggregation

PGI 2**TXA2****Increase cAMP****IP3 & DAG****Inhibits platelet
aggregation****Stimulate platelet
aggregation****Vasodilatation .****Vasoconstriction****Bronchodilation .****Bronchoconstriction****Endothelium****Platelets****Increase GFR
Diuretic
Natriuretic actions****Renal vasoconstriction
ADH-like action**

PGE2	PGF2α
IP3 & DAG or cAMP	IP3 & DAG
Vasodilatation	Vasoconstriction
Bronchodilation	Bronchoconstriction
GIT contraction	GIT contraction
Contraction of pregnant uterus	Contraction of pregnant uterus
\uparrowGFR	No action
\uparrowH2O & Na excretion	No action
Gastroprotective action	
Mediator of fever	

Uses

- **Misoprostol (PGE1)**
 - NSAID-induced gastritis (peptic ulcer)
- **alprostadiol (PGE1)**
 - Impotence, Placed in urethra (minisuppositories).
 - Maintain ductus arteriosus patent before surgery.

Dinoprostone(PGE2) Intravaginally

- induction of labour or abortion

Carboprost tromethamine (PGF2 α)

- Induction of labour or abortion
(intramuscular injection, I.M.
Intravaginally).

Epoprostenol (PGI2) I.V.

- Pulmonary hypertension
- antithrombotic (inhibit platelet aggregation)

Polypeptide autacoids

Renin -Angiotensin -Aldosterone System (RAAS)

Metabolism:

- Short duration of action
- Metabolized by aminopeptidase into Ang III& angiotensinase into peptide fragments

Actions:

Blood pressure: Hypertension

- Direct vasoconstriction
- Release of catecholamines
- +Ve inotropic effect
- Increased sympathetic outflow

Adrenal cortex:

- **aldosterone synthesis and secretion**
- **Renal blood vessels: vasoconstriction**
- **CNS: increased secretion of ADH & ACTH**

RAA blockers

- **Renin: B-blockers**
- **ACE inhibitors: captopril - enalapril**
- **Ang II blockers: losartan-candesartan**

Vasoactive polypeptides

Vasoconstrictors

Angiotensin – Endothelin-Vasopressin-
Urotensin – neuropeptide Y

Vasodilators kinins –natriuretic peptides-

Vasoactive intestinal peptide-substance

P- neurotensin - adrenomedullin

Endothelin

RECEPTORS

ET A : Smooth muscles

ET B : Vascular endothelial cells

Actions

1. Vasoconstriction
2. Direct positive inotropic and chronotropic effects.
3. Decrease GFR
4. Constriction of bronchial smooth muscles
- 5 . Increase secretion of renin, aldosterone, ANP.

Bosentan :

- **Endothelin receptor antagonist (A+B).**
- **Orally and intravenously.**
- **used for treatment of pulmonary hypertension**

The Kallikrein-Kinin System


- Present in plasma and tissues as kidney, pancreas, intestine, sweat and salivary glands.

- Kinins:

Bradykinnin – lysyl-Bradykinnin (kallidin)

- Released from high molecular weight protein precursors by kallikrein

- Degraded by kininase II, ACE



Receptors

■ B1 receptors:

- stimulated by kallidin (lys-bradykinin), bradykinin.
- Limited in mammalian tissue

■ B2 receptors:

- G-protein coupled
- mainly stimulated by bradykinin- kallidin.

Actions of Kinins

- **Mediators of inflammation (pain & oedema)**
- **Pain sensation (i.d.) by stimulation of afferents in skin**
- **Oedema**
- **Vasodilatation of arterioles (direct and via EDRF).**
- **Reflex increase HR, cardiac output, contractility.**
- **Smooth muscle contraction (the intestine, bronchi and uterus).**

USES

**kallikrein inhibitor, aprotonin (Trasylol):
acute pancreatitis, carcinoid syndrome.**